VolitionRX (NYSEAMERICAN:VNRX) Stock Price Crosses Below Fifty Day Moving Average – Here’s What Happened

VolitionRX Limited (NYSEAMERICAN:VNRX) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.68 and traded as low as $0.99. VolitionRX shares last traded at $1.00, with a volume of 176,127 shares traded.

Wall Street Analysts Forecast Growth

VNRX has been the subject of several research analyst reports. Citigroup downgraded VolitionRX to a “hold” rating in a research report on Monday, April 20th. Benchmark reissued a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. HC Wainwright lowered their price target on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Maxim Group restated a “buy” rating and issued a $4.00 price objective on shares of VolitionRX in a research report on Thursday, June 18th. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, VolitionRX currently has a consensus rating of “Hold” and an average target price of $28.00.

VolitionRX Price Performance

The stock has a market cap of $8.63 million, a price-to-earnings ratio of -0.24 and a beta of 1.12. The firm has a 50 day simple moving average of $1.68 and a two-hundred day simple moving average of $3.30.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The company had revenue of $0.99 million for the quarter, compared to analyst estimates of $1.52 million. On average, sell-side analysts expect that VolitionRX Limited will post -2.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRX

Several institutional investors and hedge funds have recently made changes to their positions in VNRX. Jane Street Group LLC bought a new stake in shares of VolitionRX in the 4th quarter valued at $28,000. Virtu Financial LLC grew its position in shares of VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 67,848 shares during the period. Squarepoint Ops LLC acquired a new position in shares of VolitionRX in the 4th quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRX during the 2nd quarter worth approximately $52,000. Finally, Citadel Advisors LLC raised its holdings in VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.